Anti-VEGF Agents Clearance Through the Aqueous Outflow Pathway in a Rat Model.
Ben-Arzi Assaf, Spector Itay, Keshet Yariv, Gal-Or Orly, Bahar Irit, Dotan Assaf
AI Summary
Anti-VEGF drugs clear completely from the eye's outflow pathway within 48 hours in rats, refuting aggregation as a cause of sustained IOP elevation.
Abstract
Purpose
Sustained increase in intraocular pressure (IOP) following intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in the treatment of retinal disease has been theoretically attributed to aggregation of anti-VEGF in the iridocorneal angle. However, previous studies by our group showed full clearance of intravitreally injected bevacizumab, aflibercept, and ranibizumab. The objective of this study was to further analyze and compare the clearance of these anti-VEGF agents from the eye after a single injection in a rat model.
Methods
Brown Norway rats received an intravitreal injection of 3 µl anti-VEGF at the standard concentration 3 days following induction of choroidal neovascularization. The eyes were processed at 0, 3, 6, 24, and 48 hours thereafter, and immunofluorescence was evaluated with confocal microscopy and 3D reconstruction analysis. The signal concentration was calculated, and the drug clearance rate was measured. The immunohistochemistry process was validated with negative and positive control groups.
Results
The immunofluorescent signal was positive for all anti-VEGF agents at the trabecular meshwork, Schlemm's canal, and episcleral veins. Anti-VEGF immunostaining peaked immediately after injection and then decreased gradually to negligible at 48 hours (P < 0.05). All three agents demonstrated an identical pattern (P > 0.05). The clearance rate of anti-VEGF from the iridocorneal angle ranged between 98.68% and 99.87% at 48 hours.
Conclusions
Bevacizumab, aflibercept, and ranibizumab cleared completely from the iridocorneal angle at 48 hours in the brown Norway rats following a single intravitreal injection and with similar a clearance rate. These findings support our earlier studies refuting the anti-VEGF aggregation hypothesis.
MeSH Terms
Shields Classification
Key Concepts4
Bevacizumab, aflibercept, and ranibizumab cleared completely from the iridocorneal angle at 48 hours in brown Norway rats following a single intravitreal injection, demonstrating a similar clearance rate.
The immunofluorescent signal for all anti-VEGF agents (bevacizumab, aflibercept, and ranibizumab) was positive at the trabecular meshwork, Schlemm's canal, and episcleral veins in brown Norway rats.
Anti-VEGF immunostaining (bevacizumab, aflibercept, and ranibizumab) peaked immediately after intravitreal injection and then decreased gradually to negligible at 48 hours (P < 0.05) in brown Norway rats.
The clearance rate of anti-VEGF agents (bevacizumab, aflibercept, and ranibizumab) from the iridocorneal angle ranged between 98.68% and 99.87% at 48 hours in brown Norway rats.
Related Articles5
Mechano- and Glucocorticoid-Sensitive TREK-1 Channels Regulate Conventional Outflow and Intraocular Pressure.
Basic ScienceMatrine Reduces Intraocular Pressure in Corticosteroid-Induced Ocular Hypertensive Mouse Eyes.
Basic ScienceNetarsudil 0.02% Alters Episcleral Venous Flowrates: A Clinical Trial Using Erythrocyte-Mediated Angiography.
Clinical TrialDrug Distribution After Intravitreal Injection: A Mathematical Model.
Basic ScienceIntracameral Injection of AAV-DJ.COMP-ANG1 Reduces the IOP of Mice by Reshaping the Trabecular Outflow Pathway.
Basic ScienceIs this article assigned to the wrong chapter(s)? Let us know.